A post-marketing observational study of ramucirumab in patients with gastric cancer in Japan.

ABSTRACT:

Background

This study evaluated the safety and effectiveness of ramucirumab monotherapy and combination therapy for advanced gastric cancer in the real-world setting.

Methods

This single-arm, prospective, multicenter, non-interventional, observational, post-marketing study was conducted in Japan from August 2015 to March 2019. Patients with unresectable advanced or recurrent gastric cancer and newly prescribed ramucirumab were followed for up to 12 months after first treatment. Data on adverse events and survival were collected via Electronic Data Capture.

Results

Of 687 enrolled patients, 658 were eligible for analysis. Most patients received either ramucirumab monotherapy (123/658; 18.7%) or ramucirumab plus paclitaxel combination therapy (528/658; 80.2%). The major

SUBMITTER: Chen Y 

PROVIDER: S-EPMC8502135 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature